Gilead Sciences, Inc.  

(Public, NASDAQ:GILD)   Watch this stock  
Find more results for gild
105.47
-0.49 (-0.46%)
After Hours: 104.98 -0.49 (-0.46%)
Sep 22, 7:59PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 104.62 - 107.57
52 week 58.81 - 110.64
Open 106.01
Vol / Avg. 12.32M/15.02M
Mkt cap 160.18B
P/E 23.69
Div/yield     -
EPS 4.45
Shares 1.53B
Beta 0.76
Inst. own 92%
Oct 28, 2014
Q3 2014 Gilead Sciences Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Sep 9, 2014
Gilead Sciences Inc at Morgan Stanley Healthcare Conference
Sep 4, 2014
Gilead Sciences Inc at Robert W. Baird & Co. Inc Health Care Conference
Sep 3, 2014
Gilead Sciences Inc at Citi Biotech Conference
Jul 23, 2014
Q2 2014 Gilead Sciences Inc Earnings Call - Webcast
Jul 23, 2014
Q2 2014 Gilead Sciences Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 55.86% 27.29%
Operating margin 67.53% 40.39%
EBITD margin - 43.46%
Return on average assets 49.40% 13.98%
Return on average equity 99.48% 29.75%
Employees 6,100 -
CDP Score - -

Address

333 LAKESIDE DR
FOSTER CITY, CA 94404
United States - Map
+1-650-5743000 (Phone)
+1-650-5789264 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead�s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company�s products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.

Officers and directors

John C. Martin Ph.D. Chairman of the Board, Chief Executive Officer
Age: 62
Bio & Compensation  - Reuters
John F. Milligan Ph.D. President, Chief Operating Officer
Age: 53
Bio & Compensation  - Reuters
Robin L. Washington Chief Financial Officer, Executive Vice President
Age: 51
Bio & Compensation  - Reuters
Norbert W. Bischofberger Ph.D. Executive Vice President - Research and Development, Chief Scientific Officer
Age: 58
Bio & Compensation  - Reuters
Gregg H. Alton Executive Vice President - Corporate and Medical Affairs
Age: 48
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Paul R. Carter Executive Vice President - Commercial Operations
Age: 53
Bio & Compensation  - Reuters
John F. Cogan Jr., Ph.d. Lead Independent Director
Bio & Compensation  - Reuters
Etienne F. Davignon Independent Director
Age: 81
Bio & Compensation  - Reuters
Carla A. Hills Independent Director
Age: 80
Bio & Compensation  - Reuters
Kevin E. Lofton Independent Director
Age: 59
Bio & Compensation  - Reuters